一项关于达沙替尼用于接受依鲁替尼治疗后病情进展的华氏巨球蛋白血症患者的初步研究。
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib.
作者信息
Castillo Jorge J, Sarosiek Shayna, Flynn Catherine A, Leventoff Carly, Little Megan, White Timothy, Meid Kirsten, Treon Steven P
机构信息
Bing Center for Waldenström Macroglobulinemia Dana-Farber Cancer Institute Boston Massachusetts USA.
Harvard Medical School Boston Massachusetts USA.
出版信息
EJHaem. 2022 Jun 7;3(3):927-929. doi: 10.1002/jha2.493. eCollection 2022 Aug.
The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 100 mg by mouth once daily in four-week cycles for up to 24 cycles. This study was registered under ClinicalTrials.Gov ID NCT04115059. Three participants were enrolled and received at least one cycle of dasatinib. The best response was stable disease. Two patients received 5 months and one patient received 1 month of therapy. The dose of dasatinib was decreased in one participant due to volume overload. Based on the lack of responses observed, the study was terminated. Dasatinib might not be effective in patients with WM progressing on ibrutinib.
造血细胞激酶（HCK）调节布鲁顿酪氨酸激酶（BTK）的激活，是华氏巨球蛋白血症（WM）的一个潜在治疗靶点。我们研究了达沙替尼（一种有效的HCK抑制剂）对接受依鲁替尼治疗后病情进展的WM患者的疗效。研究治疗方案为口服达沙替尼100毫克，每日一次，每四周为一个周期，最多进行24个周期。本研究已在ClinicalTrials.Gov注册，编号为NCT04115059。三名参与者入组并接受了至少一个周期的达沙替尼治疗。最佳反应为病情稳定。两名患者接受了5个月的治疗，一名患者接受了1个月的治疗。一名参与者因容量超负荷而降低了达沙替尼的剂量。基于观察到的无反应情况，该研究终止。达沙替尼可能对接受依鲁替尼治疗后病情进展的WM患者无效。
Zotero 插件